Exelixis Entered into an Exclusive License Agreement with Ryvu to Develop Novel STING Agonist-Based Targeted Cancer Therapies
Shots:
- Ryvu to receive a $3M up front fee in exchange for rights to Ryvu’s STING agonist small molecules & will be eligible to receive development, regulatory & commercialization milestones along with royalties
- Exelixis will be responsible for the research, development & commercialization activities upon selecting each development candidate. Ryvu will also obtain all development and commercial rights to develop its STING agonist portfolio & provide expert guidance during the partnership's first research phase
- The agreement expands Exelixis’ portfolio of biotherapeutics by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology to develop and commercialize oncology therapies
Ref: Bussinesswire | Image: Exelixis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.